The FDA raised concerns about multiple facets of the study protocol used to evaluate RGX-121, including the eligibility criteria and surrogate endpoints.
It is the first CAR-T that the agency has said is safe for this hard-to-treat subset of lymphoma patients based on data from an investigator-initiated study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results